Core Laboratories Inc.
CLB
$12.26
-$0.36-2.85%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 7.40M | 11.75M | 9.03M | 3.22M | 2.20M |
| Total Depreciation and Amortization | 3.66M | 3.68M | 3.77M | 3.84M | 3.87M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -144.00K | -1.41M | -4.64M | 8.35M | 5.12M |
| Change in Net Operating Assets | 9.69M | -915.00K | 8.99M | -9.88M | 8.24M |
| Cash from Operations | 20.62M | 13.10M | 17.15M | 5.53M | 19.43M |
| Capital Expenditure | -4.38M | -2.73M | -2.87M | -3.05M | -2.74M |
| Sale of Property, Plant, and Equipment | 802.00K | 133.00K | 208.00K | 593.00K | 65.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 20.00K | 2.11M | 1.97M | 802.00K | 225.00K |
| Cash from Investing | -3.56M | -491.00K | -687.00K | -1.66M | -2.45M |
| Total Debt Issued | 6.00M | 16.00M | 8.00M | 14.00M | 12.00M |
| Total Debt Repaid | -20.00M | -24.00M | -21.00M | -17.00M | -27.00M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -4.90M | -196.00K | -162.00K | -44.00K | -1.78M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -469.00K | -469.00K | -470.00K | -468.00K | -467.00K |
| Other Financing Activities | 0.00 | -162.00K | -45.00K | -568.00K | -1.23M |
| Cash from Financing | -19.37M | -8.83M | -13.68M | -4.08M | -18.48M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.32M | 3.78M | 2.78M | -207.00K | -1.50M |